The report "Immune Repertoire Sequencing Market by Product (Instrument, Software, Assay Kit & Reagent (TCR, BCR Kit)), Technology (Sequencing, Bioinformatics), Service (Data Analysis), Application (Research, Drug Discovery & Development) - Global Forecast to 2030", is projected to reach USD 560.5 million by 2030 from USD 354.6 million in 2025, at a CAGR of 9.6% between 2025 and 2030.
Browse 450 market data Tables and 45 Figures spread through 400 Pages and in-depth TOC on "Immune Repertoire Sequencing Market by Product (Instrument, Software, Assay Kit & Reagent (TCR, BCR Kit)), Technology (Sequencing, Bioinformatics), Service (Data Analysis), Application (Research, Drug Discovery & Development) - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/immune-repertoire-sequencing-market-151469626.html
Growth is driven by increased technological advancements and the rising focus on personalized and precision medicines, which have reshaped the approach to patient care and treatment efficacy. The increasing use of IRS in organ transplant monitoring enables better patient outcomes and more effective transplant management. Additionally, the expanding application of IRS in autoimmune disease research further supports market growth by facilitating more profound insights into disease mechanisms. A growing focus on cancer immunotherapy research drives demand for advanced IRS tools, as precision diagnostics helps develop and evaluate novel therapies. However, the market faces restraints such as the need for high capital investment, which can limit entry for smaller players and slow the pace of innovation.
The assay kits & reagents segment accounted for the largest share of the IRS products market during the forecast period.
On the basis of product, the IRS market is divided into assay kits & reagents and instruments & software. The large share of the assay kits & reagents segment can be attributed to the growing demand for reproducibility and standardization in immune profiling workflows. Moreover, as researchers and clinicians increasingly adopt IRS for applications in oncology, infectious diseases, vaccine development, and transplantation, the need for high-quality and ready-to-use kits has grown. These kits simplify complex procedures/workflow by bundling optimized reagents for sample preparation, library construction, and target enrichment, thus reducing variability and enabling more consistent results across studies and laboratories.
The research applications segment accounted for the largest share of the IRS applications market in 2024.
On the basis of application, the IRS market is segmented into research, drug discovery & development, and clinical diagnostics. The research application segment accounted for the largest IRS applications market share in 2024. The large share of this segment is attributed to the increasing use of IRS to address unmet needs in cancer and autoimmune diseases. This dominance will continue throughout the forecast period as major players develop new technologies for better oncology and autoimmune disease treatment.
The Asia Pacific is registered as the fastest-growing region in 2024.
The IRS market is divided into six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. In 2024, North America held the largest share of the IRS market, followed by Europe. The Aisa Pacific registered the highest CAGR growth within the IRS market during the forecast period owing to its increasing application for research and clinical diagnostics, the adoption of IRS for transplantation-associated research, government initiatives, and industry collaborations.
Key players in the IRS market include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), PacBio (US), Oxford Nanopore Technologies PLC (UK), 10X Genomics (US), Agilent Technologies (US), Danaher Corporation (US), Takara Bio Inc. (Japan), Azenta US Inc. (US), Adaptive Biotechnologies (US), BGI Group (China), Personalis, Inc. (US), and QIAGEN (Netherlands).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/